streptococcus pneumonia

Oritavancin diphosphate (LY333328 diphosphate) is a novel semisynthetic glycopeptide antibiotic developed for treating serious Gram-positive bacterial infections.

Tebipenem Pivoxil (Orapenem) , an orally activity carbapenem antibiotic, is utilized in treating otolaryngologic and respiratory infections.

O-Glycanase, Streptococcus pneumoniae, acts on core disaccharides containing N-acetylgalactosamine.

α2-3 Neuraminidase S, Streptococcus pneumoniae, is a glycoside hydrolase enzyme capable of hydrolyzing the glycosidic bonds of neuraminic acid.

Topoisomerase IV, Streptococcus pneumoniae (EC 5.99.1.), is produced by overexpressing its subunit in Escherichia coli.

Solithromycin (OP-1068) is an orally bioavailable antimicrobial agent that inhibits cell viability, protein synthesis, and growth rate of Streptococcus pneumoniae, Staphylococcus aureus, Staphylococcus aureus, and Haemophilus influenzae with IC50 values of 7.5 ng/mL, 40 ng/mL, and 125 ng/mL, respectively.Solithromycin inhibits protein biosynthesis by binding to the large 50S subunit of the ribosome.

Cefuroxime (Cephuroxime) is an orally active second-generation cephalosporin antibiotic with antimicrobial activity that inhibits both Gram-positive and Gram-negative bacteria, and is used in the study of soft tissue infections.

Gemifloxacin mesylate (Gemifloxacin mesylate) inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria.

Nafithromycin (WCK 4873) serves as an orally administered antibiotic effective against community-acquired pneumonia organisms such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Methicillin-susceptible Staphylococcus aureus. It displays a minimum inhibitory concentration (MIC 90) of 0.12 mg/liter against both macrolide-resistant and telithromycin-insensitive Streptococcus pneumoniae.

Grepafloxacin (OPC-17116) is a fluoroquinolone antibiotic that is administered orally. It possesses strong efficacy against community-acquired respiratory pathogens, notably Streptococcus pneumonia. Grepafloxacin exhibits excellent tissue penetration and demonstrates a promising pharmacodynamic profile.

Omadacycline, also known as PTK 0796 and Amadacyclin, is a novel first-in-class aminomethylcycline with potent activity against important skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus (MRSA), β-hemolytic streptococci, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenzae, and Legionella. Omadacycline is active against strains expressing the two main forms of tetracycline resistance (efflux and ribosomal protection). The primary effect of omadacycline is on bacterial protein synthesis, inhibiting protein synthesis with a potency greater than that of tetracycline. The binding site for omadacycline is similar to that for tetracycline.

Cefditoren Pivoxil is an orally active antibiotic with broad-spectrum antibacterial properties, and Cefditoren demonstrates potent inhibition against both Gram-negative and Gram-positive bacterial pathogens. Cefditoren exhibits a MIC50 of 0.25–0.5 mg/L against Streptococcus pneumoniae, Cefditoren is widely used for treating respiratory tract infections and skin infections. Cefditoren remains valuable in antimicrobial therapy owing to its favorable pharmacokinetic characteristics and reliable therapeutic efficacy.

Ceftaroline fosamil hydrate acetate is a powerful cephalosporin antibiotic that exhibits broad-spectrum efficacy against both Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant Streptococcus pneumoniae, and common Gram-negative bacteria. It possesses anti-infective properties suitable for studying complicated skin and skin structure infections (cSSSIs) and community-acquired bacterial pneumonia (CABP) [1] [2] [3].

Gemifloxacin mesylate (Standard) is the standard substance of Gemifloxacin mesylate, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Gemifloxacin mesylate (Gemifloxacin mesylate) inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria.

Plectasin, a peptide antibiotic derived from saprophytic fungi, can effectively kill Streptococcus pneumoniae in vitro. Additionally, it alleviates experimental peritonitis and pneumonia caused by Streptococcus pneumoniae in mice.